ADHD medicine consumption in Europe after COVID-19: catch-up or trend change?

ABSTRACT:

Background

Although the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends.

Methods

This study examines the European ADHD medication consumption in 2020 to 2022 compared to the predicted consumption assuming the persistence of pre-pandemic trends. Predictions are calculated using Seasonal Autoregressive Integrated Moving Average (SARIMA) models.

Results

While European ADHD medication sales recorded a drop in 2020, they returned to the predicted level in 2021, even slightly exceeding it. In 2022, we found a clear exceedance of the predicted level by 16.4% on average at country level. Furthermore, the increase

SUBMITTER: Gimbach S 

PROVIDER: S-EPMC10854136 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature